Positive News Sentiment NASDAQ:CMPX Compass Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.82 -0.06 (-2.08%) (As of 07/7/2022 11:19 AM ET) Add Compare Share Today's Range$2.82▼$2.8950-Day Range$1.43▼$3.1052-Week Range$1.25▼$5.40Volume531 shsAverage Volume194,162 shsMarket Capitalization$285.61 millionP/E RatioN/ADividend YieldN/APrice Target$9.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Compass Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside254.6% Upside$10.00 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$828,278 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.35) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.09 out of 5 starsMedical Sector417th out of 1,433 stocksBiological Products, Except Diagnostic Industry67th out of 220 stocks 3.5 Analyst's Opinion Consensus RatingCompass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Compass Therapeutics has a forecasted upside of 254.6% from its current price of $2.82.Amount of Analyst CoverageCompass Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.15% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Compass Therapeutics has recently decreased by 46.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPX. Previous Next 2.7 News and Social Media Coverage News SentimentCompass Therapeutics has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Compass Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -92% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $828,278.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders29.80% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.04% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.35) to ($0.56) per share.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Compass Therapeutics (NASDAQ:CMPX) StockCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Read More CMPX Stock News HeadlinesJune 26, 2022 | americanbankingnews.comB. Riley Comments on Compass Therapeutics, Inc.'s Q2 2022 Earnings (NASDAQ:CMPX)June 20, 2022 | americanbankingnews.comInsider Buying: Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Acquires 20,000 Shares of StockJune 18, 2022 | americanbankingnews.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives $10.00 Average Price Target from AnalystsJune 15, 2022 | americanbankingnews.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest UpdateJune 14, 2022 | americanbankingnews.comCompass Therapeutics, Inc. (NASDAQ:CMPX) CEO Buys $68,700.00 in StockMay 31, 2022 | finance.yahoo.comCompass Therapeutics to Present at the 2022 Jefferies Global Healthcare ConferenceMay 31, 2022 | finance.yahoo.comCompass Therapeutics to Present at the 2022 Jefferies Global Healthcare ConferenceMay 23, 2022 | finance.yahoo.comCompass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment ConferenceMay 20, 2022 | finance.yahoo.comTrade Alert: The Co-Founder Of Compass Therapeutics, Inc. (NASDAQ:CMPX), Thomas Schuetz, Has Just Spent US$50k Buying A Few More SharesMay 16, 2022 | finance.yahoo.comEntera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate StrategyMay 12, 2022 | seekingalpha.comCompass Therapeutics stock up 40% in two days following insider buysMay 9, 2022 | finance.yahoo.comHere's What Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Shareholder Ownership Structure Looks LikeMay 5, 2022 | finance.yahoo.comCompass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PTMay 3, 2022 | finance.yahoo.comCompass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009April 26, 2022 | finance.yahoo.comCompass Therapeutics Announces Appointment of Two New Directors to its BoardApril 26, 2022 | finance.yahoo.comCompass Therapeutics Announces Appointment of Two New Directors to its BoardApril 16, 2022 | finance.yahoo.comCompass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual MeetingMarch 30, 2022 | finance.yahoo.comCompass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New OrleansMarch 21, 2022 | finance.yahoo.comCompass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateMarch 12, 2022 | nasdaq.comCompass Therapeutics, Inc. Common Stock (CMPX)February 5, 2022 | finance.yahoo.comNew Capital Management LP Buys Compass Therapeutics Inc, Sells Cambria Shareholder Yield ETFJanuary 20, 2022 | msn.comFDA Gives Green Signal To Compass Therapeutics' Mid-Stage Biliary Tract Cancer Trial In USJanuary 20, 2022 | seekingalpha.comFDA clears Compass IND for mid-stage study of antibody for biliary tract cancersJanuary 20, 2022 | finance.yahoo.comCompass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)January 7, 2022 | finance.yahoo.comCompass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMPX CUSIPN/A CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees24Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today7/07/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+249.5%Consensus RatingBuy Rating Score (0-4)3 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-100.11% Return on Assets-87.13% Debt Debt-to-Equity RatioN/A Current Ratio15.03 Quick Ratio15.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book1.97Miscellaneous Outstanding Shares101,280,000Free Float71,101,000Market Cap$285.61 million OptionableNot Optionable BetaN/A Compass Therapeutics Frequently Asked Questions Should I buy or sell Compass Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Compass Therapeutics stock. View analyst ratings for Compass Therapeutics or view top-rated stocks. What is Compass Therapeutics' stock price forecast for 2022? 8 Wall Street analysts have issued 1-year price objectives for Compass Therapeutics' stock. Their CMPX stock forecasts range from $5.00 to $15.00. On average, they expect Compass Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 254.6% from the stock's current price. View analysts' price targets for Compass Therapeutics or view top-rated stocks among Wall Street analysts. How has Compass Therapeutics' stock price performed in 2022? Compass Therapeutics' stock was trading at $3.00 on January 1st, 2022. Since then, CMPX stock has decreased by 6.0% and is now trading at $2.82. View the best growth stocks for 2022 here. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) posted its quarterly earnings results on Monday, May, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.07. View Compass Therapeutics' earnings history. Who are Compass Therapeutics' key executives? Compass Therapeutics' management team includes the following people: Dr. Thomas J. Schuetz M.D., Ph.D., Co-Founder, CEO & Director (Age 61, Pay $454k)Dr. Vered Bisker-Leib MBA, Ph.D., Pres & COO (Age 51, Pay $720k)Dr. Susan Kalled Ph.D., Chief Scientific Officer (Age 61, Pay $445.5k)Mr. Neil L. Lerner CPA, VP of Fin. (Age 55)Mr. Jonathan Anderman J.D., VP, Head of Legal & Corp. Sec.Anna Gifford, Communications Mang.Dr. Peter F. Moesta Ph.D., Interim Head of CMC Who are some of Compass Therapeutics' key competitors? Some companies that are related to Compass Therapeutics include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Replimune Group (REPL), Alector (ALEC), Anavex Life Sciences (AVXL), Arcellx (ACLX), Atara Biotherapeutics (ATRA), iTeos Therapeutics (ITOS), Instil Bio (TIL), Agenus (AGEN), Coherus BioSciences (CHRS), NanoString Technologies (NSTG), Sangamo Therapeutics (SGMO), Inhibrx (INBX) and Osiris Therapeutics (OSIR). View all of CMPX's competitors. When did Compass Therapeutics IPO? (CMPX) raised $50 million in an IPO on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager. What is Compass Therapeutics' stock symbol? Compass Therapeutics trades on the NASDAQ under the ticker symbol "CMPX." How do I buy shares of Compass Therapeutics? Shares of CMPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Compass Therapeutics' stock price today? One share of CMPX stock can currently be purchased for approximately $2.82. How much money does Compass Therapeutics make? Compass Therapeutics (NASDAQ:CMPX) has a market capitalization of $285.61 million. How many employees does Compass Therapeutics have? Compass Therapeutics employs 24 workers across the globe. How can I contact Compass Therapeutics? The official website for Compass Therapeutics is www.compasstherapeutics.com. The company can be reached via phone at 617-500-8099 or via email at ir@compasstherapeutics.com. This page (NASDAQ:CMPX) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
